Safety
Seven studies reported AEs data, and almost all patients enrolled in these studies had at least one AE (98.8%). The most common treatment-emergent AEs (TEAEs) included nausea, decreased appetite, anemia, decreased neutrophil count, asthenia and vomiting, with incidences of 54.7% (95% CI: 37.0%-72.4%), 48.7% (95% CI: 33.2%-64.1%), 39.6% (95% CI: 28.6%-50.7%), 34.3% (95% CI:16.5%-52.2%), 28.5% (95% CI: 7.0%-50.1%) and 28.1% (95% CI: 20.6%-35.6%), respectively. The pooled incidence of grade 3 or higher TEAEs was 58.8% (95% CI: 43.0%-74.5%). Anemia was the most common grade ≥3 TEAE, with an incidence of 21.3% (95% CI: 12.1%-30.5%). Other common grade ≥3 TEAEs included decreased neutrophil count, decreased white blood cell count, decreased platelet count, decreased appetite and decreased lymphocyte count, the incidences of 20.4% (95% CI: 7.9%-33.0%), 12.5% (95% CI: 6.8%-18.2%), 7.5% (95% CI: 3.0%-11.9%), 6.3% (95% CI: 2.5%-10.1%) and 6.1% (95% CI: 2.3%-10.0%), respectively. A detailed description of TEAEs is presented in Table 3.
Table 3. TEAEs of the included studies